Aegerion Pharmaceuticals Observes Rare Disease Day
Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases
Get Alerts AEGR Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its alliance with the National Organization for Rare Disorders (NORD), Rare Diseases Europe (EURORDIS) and Canadian Organization of Rare Disorders (CORD), and The Global Genes Project in observance of the annual Rare Disease Day.
Chief Executive Officer Marc D. Beer commented, "We are proud to join with others in the community to raise awareness of rare diseases. We are mindful of the challenges these patients, their families and caregivers face daily, and we are motivated by a passion to support awareness, advocacy and the development of treatments for these rare diseases."
In the United States, a rare disease is defined as one that affects fewer than 200,000 persons. According to the National Institutes of Health (NIH), there are nearly 7,000 rare diseases affecting nearly 30 million Americans. Rare Disease Day was established by EURORDIS and was first observed in Europe in 2008. In 2009, EURORDIS partnered with NORD for this initiative in the U.S. For more information about Rare Disease Day, visit www.rarediseaseday.us or www.rarediseaseday.org.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Associate Director, Investor Relations & Public Relations 857-242-5024Source: Aegerion Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Front Line Medical Technologies Announces CE Marking for COBRA-OS®, Smallest Aortic Occlusion Device on the Market
- Aubex Therapeutics Launches to Revolutionize Cancer Treatment with Novel Compounds directed toward the Tumor Microenvironment
- Coastal Mississippi Invites Travelers to Unwind and Play Weekends with the Best Events of the Season
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!